These findings support the therapeutic potential of colchicine in targeting upstream NLRP3 inflammasome activation and downstream IL-1β signaling, offering a mechanistically grounded approach to mitigate inflammation-induced atrial remodeling and AF vulnerability. Here, IL1B is linked to atrial fibrillation.